Nina Shah, MD - Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/XTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of multiple myeloma experts discuss the recent changes in the multiple myeloma (MM) treatment landscape that have occurred at “warp speed” by focusing on the emergence of novel antibodies, cellular therapy, and targeted strategies across the MM treatment continuum. Throughout, the panelists engage in dedicated Tumor Board sessions designed to illustrate how professionals can apply evidence that can lead to improved patient outcomes in diverse MM patient populations and treatment settings. Upon completion of this accredited CE activity, participants should be better able to: Cite evidence surrounding the efficacy of regimens with novel proteasome inhibitors, immunomodulatory drugs, antibodies, targeted therapies, and cell therapies across multiple myeloma (MM) treatment settings, including smoldering MM, newly diagnosed MM, and relapsed/refractory MM, Select evidence-based regimens with novel components for the management of patients with newly diagnosed MM, Develop treatment plans for relapsed/refractory MM that integrate novel antibody, targeted, and CAR-T options, Manage the unique toxicities associated with innovative therapeutics in patients with MM, including cytopenias, infusion-related events, ocular toxicity, and cytokine release syndrome, among others.